viewPreveCeutical Medical Inc.

Preveceutical Medical making headway with cannabinoid delivery system

Health sciences and in particular new ways of thinking about drug delivery and disease prevention have made some significant advances in recent times.

One company on the cutting edge of preventative medicine is Vancouver based PreveCeutical Medical (CSE: PREV) (OTC: PRVCF) which focuses on innovation in the health science space.

The company's research team, led by Harry Parekh out of the R&D laboratory at the University of Queensland, has some exciting developments in drug delivery and pain management.

Preveceutical Medical is currently working on applying its Sol Gel technology to the delivery of cannabinoids to effectively treat  diseases like multiple sclerosis, paediatric epilepsy and chronic pain.

Maher Khaled, the CEO of the company's Australian arm, says the business is also looking for new opportunities as scientific evidence for cannabinoid treatments builds.

"We'll be looking at other areas and diseases where strong evidence comes to support them as we progress" says Mr Khaled.

Quick facts: PreveCeutical Medical Inc.


Price: 0.025 CAD

Market Cap: $12.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 07/23/2020

2 min read